No abstract

No abstract

Background: As the proportion of older people worldwide increases, cancer cases and deaths from cancer are rising. Suffering from cancer has a profound impact on the daily lives of patients and their families. Cancer patients often perceive themselves as a burden, which affects their quality of life; therefore, this study investigated the relationship between intolerance of uncertainty, cognitive fusion, and self-perception as burdens and the mediating role of coping self-efficacy in patients diagnosed with cancer. Methods: In this descriptive, correlational, and structural equation modeling study, 400 patient diagnosed with cancer who were hospitalized in the oncology ward of Imam Khomeini Hospital in Ardabil in the first half of 2022 were selected as the sample and answered Casino et al. self-perceived burden questionnaire, Gillanders et al. cognitive fusion questionnaire, Carleton et al. uncertainty intolerance scale, and Merleau et al. cancer behavior scale.Results: Based on the results, the fitting indices of the research conceptual model were confirmed. Intolerance of uncertainty, cognitive fusion, and coping selfefficacy had a direct and significant relationship with self-perceived burden in patients diagnosed with cancer (p < 0.01); also, intolerance of uncertainty and cognitive fusion through coping self-efficacy had an indirect effect on self-perceived burden in patients diagnosed with cancer (p < 0.05). Conclusion:Therefore, intolerance of uncertainty, cognitive fusion, and coping selfefficacy plays a substantial role in the incidence of self-perceived burden in patients diagnosed with cancer and targeting these three components by psychological therapies can reduce the perception of self-perception as burden which is effective in patients diagnosed with cancer.

Background: Coronavirus 2019 (COVID-19) vaccination is recommended for people with multiple sclerosis (MS). This study evaluated the side effects of Sinopharm and AstraZeneca vaccines in MS patients. Methods: In this cross-sectional study among MS patients in Kermanshah province, Iran, who received Sinopharm or AstraZeneca vaccine, sampling was performed through convenience sampling according to the nationwide MS registry of Iran (NMSRI). Demographic and clinical information of the participants and data on the side effects of vaccines were collected by telephone after the first dose. The data were analyzed in SPSS software. Results: 264 vaccinated MS patients (217 with Sinopharm and 47 with AstraZeneca) were studied. In the Sinopharm and AstraZeneca groups, respectively, 58.5% and 73.3% of patients had side effects that were not significantly different between the 2 groups (P = 0.064). In the AstraZeneca group, the severity of side effects and prevalence of taking painkillers were significantly higher (P < 0.050) and the interval between vaccination and side effects onset was significantly shorter (P = 0.013). The most commonly experienced side effects in the Sinopharm group were fatigue (29.0%), myalgia (24.9%), fever (24.0%), and headache (21.7%), and in the AstraZeneca group were fever (59.6%), chills (51.1%), myalgia (40.4%), and fatigue (34.0%). Logistic regression by controlling for confounding variables showed that considering some factors as confounding factors did not show a significant difference between the 2 vaccines in the experience of side effects (P = 0.104). Conclusion: The AstraZeneca vaccine caused more severe side effects in MS patients than the Sinopharm vaccine. Most of the side effects were moderate in severity and transient.